Interim Report January - March 2008

Interim Report January - March 2008

• Group income from sales of goods and royalties amounted to 289 (300) MSEK. 

• Operating income amounted to 10 (56) MSEK.

• Revenues within the Esthetics product area amounted to 233 (240) MSEK and
operating income was 55 (88) MSEK.

• Net income after tax amounted to 10 (42) MSEK.

• Earnings per share amounted to 0.10 (0.42) SEK.

• As from April 1, 2008 all North American insurance companies reinsure
endoscopic treatment of VUR (Deflux®).

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™, for the production of stabilized non-animal hyaluronic acid.
The product portfolio today contains: Restylane® for filling lines and folds,
contouring and creating volume in the face, Macrolane™ for body shaping,
Durolane™ for the treatment of osteoarthritis of the hip and knee joints,
Deflux™ for the treatment of vesicoureteral reflux, VUR, (a malformation of the
urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.